文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗中重度斑块状银屑病的真实世界多中心前瞻性研究

A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
PubMed 文献 · J Am Acad Dermatol · 2019-03-11

该研究在西班牙12家医院纳入158例中重度斑块状银屑病成人患者,前瞻性随访52周。结果显示司库奇尤单抗安全,疗效与3期研究相似,第52周PASI-75和PASI-90应答率分别为78.5%和63.2%,且疗效可持续至治疗1年。

要点

  • 司库奇尤单抗在真实临床实践中安全,52周疗效与3期研究相似。
  • 第52周PASI-75和PASI-90应答率分别为78.5%和63.2%。
  • BMI<30 kg/cm²且无既往生物制剂失败者应答更佳。

核心结论

  • 司库奇尤单抗是安全的治疗选择,其疗效与3期研究相似,且疗效可持续至治疗开始后1年。

研究设计与样本

  • 多中心前瞻性观察性研究,2016年1月至12月从西班牙12家医院招募158例中重度斑块状银屑病成人患者,每12周随访至52周。

主要发现

  • 第4、12、24、52周达到PASI-75的患者比例分别为57%、83.5%、89%、78.5%。
  • 第4、12、24、52周达到PASI-90的患者比例分别为27.8%、62%、64.6%、63.2%。
  • BMI<30 kg/cm²的患者及无既往生物制剂治疗失败的患者中PASI-75和PASI-90应答显著更常见。

临床怎么用

  • 真实临床中可预期司库奇尤单抗对中重度斑块状银屑病在1年内维持较高应答率,BMI<30且无既往生物制剂失败者应答更优。

局限性

  • 本研究为观察性研究,未评估银屑病发病时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. OBJECTIVE: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. METHODS: In this multicenter prospective observational study, we recruited adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. RESULTS: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement ≥75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index <30 kg/cm2 and patients without previous biologic therapy failures. LIMITATIONS: Observational study. Time from onset of psoriasis was not evaluated. CONCLUSION: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019. PMID: 30872150. doi:10.1016/j.jaad.2019.02.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。